CRNX Key Statistics, Chart & Performance
The current stock price of CRNX is 47.43 USD. In the past month the price increased by 3.22%. In the past year, price increased by 28.26%.
CRNX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CRNX. When comparing the yearly performance of all stocks, CRNX is one of the better performing stocks in the market, outperforming 82.87% of all stocks.
CRNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRNX. While CRNX has a great health rating, there are worries on its profitability.
CRNX Financial Highlights
Over the last trailing twelve months CRNX reported a non-GAAP Earnings per Share(EPS) of -4.53. The EPS decreased by -21.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.38% | ||
| ROE | -39.46% | ||
| Debt/Equity | 0 |
CRNX Forecast & Estimates
22 analysts have analysed CRNX and the average price target is 85.75 USD. This implies a price increase of 80.8% is expected in the next year compared to the current price of 47.43.
For the next year, analysts expect an EPS growth of -37.84% and a revenue growth 274.52% for CRNX
CRNX Ownership
CRNX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 32.98 | 1.047T | ||
| JNJ | JOHNSON & JOHNSON | 20.28 | 564.909B | ||
| MRK | MERCK & CO. INC. | 21.87 | 293.697B | ||
| PFE | PFIZER INC | 8.92 | 152.263B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 117.3B | ||
| ZTS | ZOETIS INC | 18.49 | 55.835B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.42 | 25.214B | ||
| VTRS | VIATRIS INC | 5.69 | 16.539B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.14 | 12.123B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.14 | 9.353B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRNX
Company Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 437 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Company Info
CRINETICS PHARMACEUTICALS IN
6055 Lusk Blvd.
San Diego CALIFORNIA 92121 US
CEO: R. Scott Struthers
Employees: 437
Phone: 18584506464
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What does CRINETICS PHARMACEUTICALS IN do?
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 437 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Can you provide the latest stock price for CRINETICS PHARMACEUTICALS IN?
The current stock price of CRNX is 47.43 USD. The price decreased by -5.06% in the last trading session.
Does CRNX stock pay dividends?
CRNX does not pay a dividend.
What is the ChartMill rating of CRINETICS PHARMACEUTICALS IN stock?
CRNX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is CRINETICS PHARMACEUTICALS IN (CRNX) stock traded?
CRNX stock is listed on the Nasdaq exchange.
What is the next earnings date for CRNX stock?
CRINETICS PHARMACEUTICALS IN (CRNX) will report earnings on 2026-02-26, after the market close.